Cargando…

Remission of aHUS neurological damage with eculizumab

Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ávila, Ana, Vizcaíno, Belén, Molina, Pablo, Gavela, Eva, Perez-Ebri, Maria, Pallardó, Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370300/
https://www.ncbi.nlm.nih.gov/pubmed/25815183
http://dx.doi.org/10.1093/ckj/sfu144
_version_ 1782362851178971136
author Ávila, Ana
Vizcaíno, Belén
Molina, Pablo
Gavela, Eva
Perez-Ebri, Maria
Pallardó, Luís
author_facet Ávila, Ana
Vizcaíno, Belén
Molina, Pablo
Gavela, Eva
Perez-Ebri, Maria
Pallardó, Luís
author_sort Ávila, Ana
collection PubMed
description Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being accompanied by signs of extrarenal thrombotic microangiopathy (TMA). We report a case of full neurological and haematological recovery after eculizumab treatment in a patient with ESRD secondary to chronic aHUS refractory to plasmatherapy while she was under dialysis. It highlights the use of eculizumab for controlling extrarenal manifestations of aHUS in this population.
format Online
Article
Text
id pubmed-4370300
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43703002015-03-26 Remission of aHUS neurological damage with eculizumab Ávila, Ana Vizcaíno, Belén Molina, Pablo Gavela, Eva Perez-Ebri, Maria Pallardó, Luís Clin Kidney J Contents Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being accompanied by signs of extrarenal thrombotic microangiopathy (TMA). We report a case of full neurological and haematological recovery after eculizumab treatment in a patient with ESRD secondary to chronic aHUS refractory to plasmatherapy while she was under dialysis. It highlights the use of eculizumab for controlling extrarenal manifestations of aHUS in this population. Oxford University Press 2015-04 2015-01-22 /pmc/articles/PMC4370300/ /pubmed/25815183 http://dx.doi.org/10.1093/ckj/sfu144 Text en © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Contents
Ávila, Ana
Vizcaíno, Belén
Molina, Pablo
Gavela, Eva
Perez-Ebri, Maria
Pallardó, Luís
Remission of aHUS neurological damage with eculizumab
title Remission of aHUS neurological damage with eculizumab
title_full Remission of aHUS neurological damage with eculizumab
title_fullStr Remission of aHUS neurological damage with eculizumab
title_full_unstemmed Remission of aHUS neurological damage with eculizumab
title_short Remission of aHUS neurological damage with eculizumab
title_sort remission of ahus neurological damage with eculizumab
topic Contents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370300/
https://www.ncbi.nlm.nih.gov/pubmed/25815183
http://dx.doi.org/10.1093/ckj/sfu144
work_keys_str_mv AT avilaana remissionofahusneurologicaldamagewitheculizumab
AT vizcainobelen remissionofahusneurologicaldamagewitheculizumab
AT molinapablo remissionofahusneurologicaldamagewitheculizumab
AT gavelaeva remissionofahusneurologicaldamagewitheculizumab
AT perezebrimaria remissionofahusneurologicaldamagewitheculizumab
AT pallardoluis remissionofahusneurologicaldamagewitheculizumab